Grant Details

GRANT OVERVIEW

Grant name and funding organization

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research

National Institutes of Health (NIH)

Total funding amount and duration

Total funding amount: $150,000 per year

Maximum project period: 3 years

Primary objective and mission statement

To support exploratory research projects focused on developing innovative technologies for improving the quality and handling of cancer-relevant biospecimens.

Key stakeholders and beneficiaries

National Cancer Institute (NCI)

Researchers in cancer biology, clinical diagnosis, and treatment

ELIGIBILITY CRITERIA

Organization Requirements

Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local governments, state governments, and tribal governments.

Non-domestic (non-U.S.) entities are also eligible to apply.

Geographic Scope

Open to U.S. and non-U.S. organizations.

Project Requirements

Focus on early-stage development of innovative technologies for biospecimen handling.

Projects must address unmet needs in cancer research.

Financial Requirements

Application budgets are limited to $150,000 per year in direct costs.

Timeline Requirements

Application deadline: October 3, 2025.

Earliest start date: April 4, 2025.

Previous Funding Considerations

No restrictions on prior grant funding mentioned.

APPLICATION PROCESS

Required documentation and materials

Follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.

Evaluation criteria and scoring system

Applications will be evaluated based on significance, innovation, rigor, and feasibility.

Review process and timeline

Applications will undergo scientific peer review and receive a written critique.

Selection criteria and priorities

Scientific and technical merit of the proposed project will be considered.

SPECIAL CONSIDERATIONS

Unique aspects or requirements

Projects must include quantitative performance measures.

Potential challenges or limitations

Applications proposing traditional biological-hypothesis driven research will not be reviewed.

Strategic alignment opportunities

Projects that address cancer health disparities are encouraged.

Competitive advantages or disadvantages

Innovative technologies with high potential impact are prioritized.

KEY INSIGHTS AND RECOMMENDATIONS

Critical success factors

Demonstrating innovative capabilities and addressing unmet needs in cancer research.

Common pitfalls to avoid

Avoid submitting applications that lack novelty in technical capabilities.

Strategic recommendations for applicants

Engage with NIH contacts for guidance on project alignment with funding priorities.

Competitive positioning advice

Highlight the transformative potential of the proposed technology.

Grant Details

cancer biospecimen research healthcare innovation clinical research technology development health disparities
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
RFA-CA-25-003
Innovative Molecular Analysis Technologies (IMAT) Program
UNIVERSITY NGO ENTERPRISE SME PUBLIC OTHER
US AF AL DZ AS AD AO AI AQ AG AR AU AT BY BE BG CA CN HR CY CZ DK EG EE FI FR GE DE GI GR HU IS IE IL IT JP LV LI LT LU MK MY MT MX MD NL NZ NO PL PT QA RO SA SC SG SK SI ES SE CH TR UA AE UK VA VG VI
RESEARCH_DEVELOPMENT
False
150000.00
None
150000.00
USD
None
True
False
The expected impact includes advancements in cancer research methodologies and improved handling of biospecimens, leading to better outcomes in cancer diagnosis and treatment.
Deliverables include the development of innovative tools and technologies for biospecimen handling and performance measures for assessing their effectiveness.
Oct. 3, 2025, 10 p.m.
October 2025 - December 2025
Follow the instructions in the How to Apply - Application Guide.
True
Applications will be evaluated based on significance, innovation, rigor, and feasibility.
Projects must demonstrate innovative capabilities and address unmet needs in cancer research.
Technical feasibility of the proposed technology should be established.
Projects should have the potential for significant impact on cancer research and clinical practice.
False
False
R61 Phase 1 Exploratory/Developmental Grant
Recipients must comply with NIH Grants Policy Statement and other applicable regulations.
Annual reporting on project progress and financial statements.
Payments will be made in accordance with NIH policies.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act.
No additional sector-specific requirements mentioned.